Primary Immune Thrombocytopenic Purpura (ITP) and ITP Associated with Systemic Lupus Erythematosus: A Review of Clinical Characteristics and Treatment Modalities.
Document Type
Article
Publication Date
3-1-2024
Publication Title
International Journal of Rheumatology
Abstract
Immune thrombocytopenic purpura (ITP) is an immune-mediated disorder characterized by the destruction of platelets and megakaryocytes due to autoantibodies against the platelet surface proteins. ITP without any apparent cause of thrombocytopenia is defined as primary ITP, and ITP in the setting of SLE is secondary ITP, which can be diagnosed after excluding other causes of thrombocytopenia by history, physical examination, and laboratory testing. Patients with ITP associated with SLE have higher median platelet count and less bleeding manifestations compared to the patients with primary ITP. It can be very challenging to diagnose primary ITP in SLE patients as other causes of thrombocytopenia including drug-induced thrombocytopenia, antiphospholipid syndrome, and thrombotic microangiopathic process should be ruled out. Corticosteroids are the main modality of treatment. IVIG can be used in severe cases. Splenectomy was found to be less effective in ITP associated with SLE compared to primary ITP. Control of disease activity with immunosuppressive therapy can be helpful in some cases associated with active disease flares in SLE patients.
Volume
2024
First Page
6650921
Recommended Citation
Bashyal KP, Shah S, Ghimire C, Balmuri S, Chaudhary P, Karki S, et al. [Pokharel A]. Primary immune thrombocytopenic purpura (ITP) and ITP associated with systemic lupus erythematosus: a review of clinical characteristics and treatment modalities. Int J Rheumatol. 2024 Mar 1;2024:6650921. doi: 10.1155/2024/6650921. PMID: 38464849.
DOI
10.1155/2024/6650921
ISSN
1687-9260
PubMed ID
38464849
